Literature DB >> 7700630

CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.

Q Liu1, S Neuhausen, M McClure, C Frye, J Weaver-Feldhaus, N A Gruis, K Eddington, M J Allalunis-Turner, M H Skolnick, F K Fujimura.   

Abstract

Tumor suppressor gene CDKN2 (also called MTS1, CDK4I and p16INK4) is located in 9p21 and deleted homozygously in a high percentage of tumor cell lines. We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2. Overall, 18% (27/154) of the cell lines carried mutations in CDKN2. These mutations were found in cell lines derived from melanoma, bladder, lung and prostate cancers, as well as sarcomas of various origin. The spectrum of the CDKN2 mutations found in melanoma cell lines indicated a major role for ultraviolet light in generating the mutations, suggesting the mutations occurred in vivo. The frequency of loss of heterozygosity in 9p21 in this set of lines is only slightly higher than the background rate of aneuploidy, suggesting that a second 9p21 tumor suppressor gene, if it exists, must lie near CDKN2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7700630

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis.

Authors:  E K Goldberg; J M Glendening; Z Karanjawala; A Sridhar; G J Walker; N K Hayward; A J Rice; D Kurera; Y Tebha; J W Fountain
Journal:  Am J Hum Genet       Date:  2000-07-29       Impact factor: 11.025

2.  The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Authors:  W M Stadler; O I Olopade
Journal:  Urol Res       Date:  1996

3.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.

Authors:  E Hara; R Smith; D Parry; H Tahara; S Stone; G Peters
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  p53 and p16INK4A mutations during the progression of glomus tumor.

Authors:  S Güran; E T Tali
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.

Authors:  Noboru Konishi; Mitsutoshi Nakamura; Munehiro Kishi; Masayoshi Nishimine; Eiwa Ishida; Keiji Shimada
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

6.  Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.

Authors:  D Parry; G Peters
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

7.  High frequency of aberrant p16(INK4A) expression in human breast cancer.

Authors:  J Geradts; P A Wilson
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

8.  Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.

Authors:  Y Nakao; X Yang; M Yokoyama; A Ferenczy; S C Tang; M M Pater; A Pater
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs.

Authors:  Jesús Aguirre-Hernández; Bruce S Milne; Chris Queen; Patricia C M O'Brien; Tess Hoather; Sean Haugland; Malcolm A Ferguson-Smith; Jane M Dobson; David R Sargan
Journal:  BMC Vet Res       Date:  2009-07-31       Impact factor: 2.741

10.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.

Authors:  G M Maelandsmo; V A Flørenes; E Hovig; T Oyjord; O Engebraaten; R Holm; A L Børresen; O Fodstad
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.